

Genetic Testing for Hereditary Cancer CPT® Code Update

Return to [Genetic testing for hereditary cancer unproven codes](#).

Effective Date: Dec. 1, 2020

Applicable Codes

Effective Dec. 1, 2020, 11 codes will deny as “unproven per medical policy” and will not be reimbursable regardless of prior authorization status.

CPT Code	Description
Mulfi-Gene Panel	
0101U	Hereditary colon cancer disorders (e.g., Lynch syndrome PTEN hamartoma syndrome Cowden syndrome familial adenomatosis polyposis) genomic sequence analysis panel utilizing a combination of NGS Sanger MLPA and array CGH with mRNA analytics to resolve variants of unknown significance when indicated (15 genes [sequencing and deletion/duplication] EPCAM and GREM1 [deletion/duplication only])
0102U	Hereditary breast cancer-related disorders (e.g., hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer) genomic sequence analysis panel utilizing a combination of NGS Sanger MLPA and array CGH with mRNA analytics to resolve variants of unknown significance when indicated (17 genes [sequencing and deletion/duplication])
0103U	Hereditary ovarian cancer (e.g., hereditary ovarian cancer, hereditary endometrial cancer) genomic sequence analysis panel utilizing a combination of NGS Sanger MLPA and array CGH with mRNA analytics to resolve variants of unknown significance when indicated (24 genes [sequencing and deletion/duplication] EPCAM [deletion/duplication only])
0130U	Hereditary colon cancer disorders (e.g., Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis), targeted mRNA sequence analysis panel (APC, CDH1, CHEK2, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, and TP53) (List separately in addition to code for primary procedure)
0131U	Hereditary breast cancer-related disorders (e.g., hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (13 genes) (List separately in addition to code for primary procedure)
0132U	Hereditary ovarian cancer-related disorders (e.g., hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (17 genes) (List separately in addition to code for primary procedure)
0133U	Hereditary prostate cancer-related disorders, targeted mRNA sequence analysis panel (11 genes) (List separately in addition to code for primary procedure)
0134U	Hereditary pancreatic cancer (e.g., hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (18 genes) (List separately in addition to code for primary procedure)
0135U	Hereditary gynecological cancer (e.g., hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (12 genes) (List separately in addition to code for primary procedure)

CPT® is a registered trademark of the American Medical Association

CPT Code	Description
BRCA1 and BRCA2, Lynch syndrome	
0138U	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (e.g., hereditary breast and ovarian cancer) mRNA sequence analysis (List separately in addition to code for primary procedure)
0162U	Hereditary colon cancer (Lynch syndrome), targeted mRNA sequence analysis panel (MLH1, MSH2, MSH6, PMS2) (List separately in addition to code for primary procedure)

CPT[®] is a registered trademark of the American Medical Association